Advancing cancer drug discovery towards more agile development of targeted combination therapies.

Current drug-discovery strategies are typically 'target-centric' and are based upon high-throughput screening of large chemical libraries against nominated targets and a selection of lead compounds with optimized 'on-target' potency and selectivity profiles. However, high attrition of targeted agents in clinical development suggest that combinations of targeted agents will be most effective in treating solid tumors if the biological networks that permit cancer cells to subvert monotherapies are identified and retargeted. Conventional drug-discovery and development strategies are suboptimal for the rational design and development of novel drug combinations. In this article, we highlight a series of emerging technologies supporting a less reductionist, more agile, drug-discovery and development approach for the rational design, validation, prioritization and clinical development of novel drug combinations.

[1]  Michelle L. Reyzer,et al.  Direct molecular analysis of whole-body animal tissue sections by MALDI imaging mass spectrometry. , 2010, Methods in molecular biology.

[2]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[3]  Tze Leung Lai,et al.  Adaptive trial designs. , 2012, Annual review of pharmacology and toxicology.

[4]  P. Jänne,et al.  Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.

[5]  David A. Tuveson,et al.  The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics , 2006, Clinical Cancer Research.

[6]  Angela Greco,et al.  A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.

[7]  Neil O Carragher,et al.  High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells , 2010, Molecular Cancer Therapeutics.

[8]  Lani F. Wu,et al.  Multidimensional Drug Profiling By Automated Microscopy , 2004, Science.

[9]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[10]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[11]  Li Mao,et al.  Algorithmic Guided Screening of Drug Combinations of Arbitrary Size for Activity against Cancer Cells , 2022 .

[12]  W. Pao,et al.  How genetically engineered mouse tumor models provide insights into human cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[14]  H. Erfle,et al.  Reverse transfection on cell arrays for high content screening microscopy , 2007, Nature Protocols.

[15]  E. Butcher,et al.  Can cell systems biology rescue drug discovery? , 2007, Ernst Schering Research Foundation workshop.

[16]  Sergey E Ilyin,et al.  High-Throughput siRNA-Based Functional Target Validation , 2004, Journal of biomolecular screening.

[17]  Marc Bickle,et al.  High-content screening: a new primary screening tool? , 2008, IDrugs : the investigational drugs journal.

[18]  John A. Tallarico,et al.  Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.

[19]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[20]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[21]  Zhiwei Wang,et al.  Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations , 2010, Molecular Cancer Therapeutics.

[22]  Christian Holz,et al.  Exploring the Full Power of Combining High Throughput RNAi with High Content Readouts: From Target Discovery Screens to Drug Modifier Studies , 2007 .

[23]  Stephen H. Friend,et al.  How molecular profiling could revolutionize drug discovery , 2005, Nature Reviews Drug Discovery.

[24]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[25]  M. Vieth,et al.  Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.

[26]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[27]  Urs Eppenberger,et al.  Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts , 2006, Proteomics.

[28]  X. Xie,et al.  Video-Rate Molecular Imaging in Vivo with Stimulated Raman Scattering , 2010, Science.

[29]  Bernhard Lendl,et al.  Raman spectroscopy in chemical bioanalysis. , 2004, Current opinion in chemical biology.

[30]  Sohita Dhillon,et al.  Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. , 2011, Drugs.

[31]  A. Manz,et al.  Lab-on-a-chip: microfluidics in drug discovery , 2006, Nature Reviews Drug Discovery.

[32]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[33]  T. Chou,et al.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. , 2005, European journal of biochemistry.

[34]  Fan Zhang,et al.  Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy , 2010, Clinical Cancer Research.

[35]  J. Baselga,et al.  Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[37]  Torsten Luksch,et al.  Nucleophilic catalysis of acylhydrazone equilibration for protein-directed dynamic covalent chemistry. , 2010, Nature chemistry.

[38]  T. Mitchison,et al.  A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods , 2004, BMC biotechnology.

[39]  J. Dancey,et al.  Strategies for optimizing combinations of molecularly targeted anticancer agents , 2006, Nature Reviews Drug Discovery.

[40]  N. Carragher,et al.  Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery , 2011, Pharmaceutics.

[41]  Edward P. Jaeger,et al.  Application of Genetic Algorithms to Combinatorial Synthesis: A Computational Approach to Lead Identification and Lead Optimization†,∇ , 1996 .

[42]  Markus Ehrat,et al.  Antibody‐based proteomics , 2009, The FEBS journal.

[43]  Roberto Guerrieri,et al.  Dielectrophoresis-based 'Lab-on-a-chip' devices for programmable binding of microspheres to target cells. , 2005, International journal of oncology.

[44]  Wei Zhang,et al.  A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.

[45]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[46]  Monika Sramkova,et al.  Intravital microscopy: a novel tool to study cell biology in living animals , 2010, Histochemistry and Cell Biology.

[47]  Olof Ramström,et al.  Drug discovery by dynamic combinatorial libraries , 2002, Nature Reviews Drug Discovery.

[48]  Walter A. Korfmacher,et al.  Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. , 2003, Journal of mass spectrometry : JMS.

[49]  Alistair Elfick,et al.  Raman Spectroscopy and Related Techniques in Biomedicine , 2010, Sensors.

[50]  L. Weber,et al.  Applications of genetic algorithms in molecular diversity. , 1998, Current opinion in chemical biology.

[51]  Walter Kolch,et al.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer , 2010, Nature Reviews Cancer.

[52]  K. Anderson,et al.  Use of photoactivation and photobleaching to monitor the dynamic regulation of E-cadherin at the plasma membrane , 2010, Cell adhesion & migration.

[53]  A. Maggi,et al.  Reporter mice and drug discovery and development , 2005, Nature Reviews Drug Discovery.

[54]  Philip E. Bourne,et al.  A Multidimensional Strategy to Detect Polypharmacological Targets in the Absence of Structural and Sequence Homology , 2010, PLoS Comput. Biol..

[55]  R. Hargreaves,et al.  Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[56]  Daniel Rauh,et al.  An Unbiased Cell Morphology–Based Screen for New, Biologically Active Small Molecules , 2005, PLoS biology.

[57]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[58]  Andrew Bullen,et al.  Microscopic imaging techniques for drug discovery , 2008, Nature Reviews Drug Discovery.

[59]  N. Carragher.  Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover , 2009, Clinical & Experimental Metastasis.

[60]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[61]  R. B. Hamilton,et al.  Strengthening clinical cancer research in the United Kingdom , 2011, British Journal of Cancer.

[62]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[63]  R. Weissleder,et al.  Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging , 2002, European Radiology.

[64]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[65]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[66]  A. Friedman,et al.  Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme , 2004, Clinical Cancer Research.

[67]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.